Madrigal pads MASH pipeline with six siRNAs from China's Ribo
Madrigal以manbetx3.0 苏州力博生命科学的六种siRNA充实其MASH研发管线

Madrigal Pharmaceuticals is on a mission to become a generational, independent player in the MASH field with its third deal in eight months.
Madrigal Pharmaceuticals正致力于通过在八个月内达成第三笔交易，成为MASH领域具代际影响力的独立参与者。